Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion
- 1 February 1993
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 341 (8844) , 507-511
- https://doi.org/10.1016/0140-6736(93)90274-k
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2Journal of the American College of Cardiology, 1992
- Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trialJournal of the American College of Cardiology, 1992
- Thrombolyis for pulmonary embolismThe Lancet, 1992
- Pulmonary embolism thromboiysis: A clarion call for international collaborationJournal of the American College of Cardiology, 1992
- Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: A European multicenter double-blind trialJournal of the American College of Cardiology, 1992
- Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). The PIOPED InvestigatorsJAMA, 1990
- RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISMThe Lancet, 1988
- Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activatorJournal of the American College of Cardiology, 1987
- ACUTE PULMONARY EMBOLISM TREATED WITH TISSUE PLASMINOGEN ACTIVATORThe Lancet, 1986
- A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency TablesJournal of the American Statistical Association, 1983